|
NR 4-6/2007
|
|
|
|
|
|
|
|
|
Doszklistkowe
iniekcje bevacizumabu (Avastin) w leczeniu wysiękowej formy
zwyrodnienia plamki związanego z wiekiem (AMD) – doniesienie
wstępne
Intravitreal bevacizumab (Avastin)
iniections for neovascular age-related macular degeneration (AMD)
– preliminary results
Jerzy Mackiewicz, Anna Mańkowska, Joanna
Dolar-Szczasny, Anna Zubilewicz, Agnieszka Oleszczuk, Katarzyna
Nowomiejska, Robert Rejdak, Zbigniew Zagórski
Z Katedry i I Kliniki Okulistyki Akademii Medycznej w Lublinie
Kierownik: dr hab. n. med. Tomasz Żarnowski |
|
|
| Summary: |
Purpose: To evaluate
effects of intravitreal bevacizumab on visual acuity and
angiographic lesions characteristics in patients with
neovascular AMD and to report safety of such treatement.
Material and methods: 32 patients with confirmed
choroidal neovascularisation (CNV) and AMD were treated.
Patients received 2 intravitreal bevacizumabu (1.25 mg)
iniections on 1-3 months basis. Control ophthalmic
evaluations included visual acuity measurements with
EDTRS charts, intraocular pressure measurements,
complete ophthalmic examination in slit lamp,
fluorescein angiography and blond pressure measurements.
Results: In 18 patients (56%) visual acuity improvement
at a mean 3 lines on EDTRS charts was observed, in 9
patients (28%) visual acuity did not change and in 5
(16%) cases decreased visual acuity (about 1,5 lines in
EDTRS charts) was noted. Mean follow-up period was 3
months after second injection. In most study eyes
fluorescein angiography revealed a marked reduction in
leakage from CNV. Apart from one case with
endophthalmitis symptoms after second bevacizumab
injection, we did not observed systemic or ocular
adverse effects of the applied treatment.
Conclusions: Short-term results suggest that
intravitreal bevacizumab is relatively safe form of AMD
treatement and is associated with improvement in visual
acuity and reduction in angiographic leakage in most
patients with neovascular AMD. Further evaluation of the
long-term effectiveness of this treatment is warranted. |
| Słowa kluczowe: |
naczyniowy czynnik wzrostu
śródbłonka (VEGF), neowaskularyzacja podsiatkówkowa,
zwyrodnienie plamki związane z wiekiem (AMD),
bevacizumab. |
| Key words: |
vascular endothelial
growth factor (VEGF), choroidal neovascularisation
(CNV), age-related macular degeneration (AMD),
bevacizumab. |
|
|
|
|
|
|
